Cargando…

1166. The Cost-Effectiveness Evidence of Enhanced Influenza Vaccines in Adults ≥65 Years of Age: A Literature Review and Decision-Making Implications

BACKGROUND: Older individuals have high rates of seasonal influenza-related hospitalizations and deaths. For this population, enhanced vaccines have been designed to mitigate the effect of age-related immunosenescence by providing higher immunogenicity and increased relative vaccine effectiveness (r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giglio, David FismanNorberto, Márquez-Peláez, Sergio, Nguyen, Van, Postma, Maarten, Pugliese, Andrea, Ruiz-Aragón, Jesús, urueña, Analia, Mould-Quevedo, Joaquin F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679069/ http://dx.doi.org/10.1093/ofid/ofad500.1006

Ejemplares similares

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
por: Postma, Maarten, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
por: Urueña, Analía, et al.
Publicado: (2022)

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018)

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
por: Levin, Myron J., et al.
Publicado: (2021)

14. A Comprehensive Real-World Analysis to Compare Adjuvanted Trivalent Influenza Vaccine and Trivalent High Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2018–19 Season among U.S. Elderly
por: Postma, Maarten, et al.
Publicado: (2020)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States
por: Divino, Victoria, et al.
Publicado: (2021)

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom
por: Maschio, Michael, et al.
Publicado: (2022)

6. MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018–19 Influenza Season
por: Pelton, Stephen I, et al.
Publicado: (2020)

Estimating the Impact of Influenza Vaccination on Acute and ICU Hospital Bed Usage in an Influenza Season under Endemic COVID-19 in the US
por: Nguyen, Van Hung, et al.
Publicado: (2022)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

1732. The Value of the Influenza Cell-Based Vaccine in the Pediatric Population. A Dynamic Transmission Modelling Approach in the U.S.
por: Mould-Quevedo, Joaquin F, et al.
Publicado: (2023)

Experience of 1166 Thyroidectomy without Use of Prophylactic Antibiotic
por: Lu, Qiang, et al.
Publicado: (2014)

Estimating the impact of influenza vaccination of low-risk 50–64-year-olds on acute and ICU hospital bed usage in an influenza season under endemic COVID-19 in the UK
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary adenomas
por: Wang, Fuyu, et al.
Publicado: (2014)

The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach
por: Nguyen, Van Hung, et al.
Publicado: (2021)

The Impact of Adjuvanted Influenza Vaccine on Disease Severity in the US: A Stochastic Model
por: Pelton, Stephen I., et al.
Publicado: (2023)

Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review
por: Mould-Quevedo, Joaquin F., et al.
Publicado: (2023)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
por: Giorgi, Mariano Anibal, et al.
Publicado: (2015)

1167. The Value of Influenza Vaccination in the Older Adult Population. A Stochastic Model Estimation of the benefit of vaccination to prevent the Severe Outcomes in the U.S.
por: Pelton, Stephen I, et al.
Publicado: (2023)

Meningococcal burden of disease in Argentina: 10 years epidemiologic review
por: Neyro, Silvina, et al.
Publicado: (2023)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

1166. Infection Rate in Venous–Venous Extracorporeal Membrane Oxygenation (VV-ECMO)
por: Wang, Joseph, et al.
Publicado: (2019)

1166. Evaluating the Impact of the 2016 Candidemia Guidelines on the Incidence of Ocular Complications of Candidemia
por: Hillenbrand, Molly, et al.
Publicado: (2020)

1166. Reverse Syphilis Screening and Adherence to The Congenital Syphilis Guidelines: Institutional Experience
por: Chatani, Brandon, et al.
Publicado: (2021)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Test a vide des traversees dessin SI-3-76-1166-2D
por: Riboni, P, et al.
Publicado: (1977)

AT1R A1166C variants in patients with type 2 diabetes mellitus and diabetic nephropathy
por: Moradi, Mahmoudreza, et al.
Publicado: (2015)

Association of Central Obesity with Sex Hormonebinding Globulin: A Cross-sectional Study of 1166 Chinese Men
por: Liu, Fangwei, et al.
Publicado: (2018)

Protective effect of early immunomodulatory treatment on ocular involvement in Behcet's disease: Historical cohort of 1166 patients
por: Tehrani-Banihashemi, Arash, et al.
Publicado: (2023)

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
por: Bindels, Jill, et al.
Publicado: (2015)

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Epidemiological study of influenza virus infections in young adult outpatients from Buenos Aires, Argentina
por: Santamaría, Cecilia, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_6iunle401qdrf3pn7qkam4cpe2